Skip to main content

2023 SSO Annual Meeting Main banner

Tweets by 2023 SSO Annual Meeting

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Speaker

Browse by Speaker

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Z
Zafar, Syed Nabeel

University of Wisconsin-Madison
43: Optimal Duration of Chemotherapy in the Era of Neoadjuvant Therapy for Pancreatic Adenocarcinoma - Is There a Magic Number?
Location:Ballroom B
Syed Nabeel Zafar
Disparities Poster Presentations
Location:SSO HUB: Rare/Metastatic Cancers Zone
Syed Nabeel Zafar
Zager, Jonathan

H. Lee Moffitt Cancer Center
58: Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?
Location:Veterans Memorial Auditorium
Jonathan Zager
P41: A Multi-Institution Observational Analysis of the Theory of the Immunization Effect in Patients with Multiple Primary Melanomas
Location:SSO HUB: Melanoma & Sarcoma Zone
Jonathan Zager
Rebuttal and Q&A
Location:Ballroom C
Jonathan Zager
Still Has a Role
Location:Ballroom C
Jonathan Zager
Zaghloul, Ashraf

National Cancer Institute, Cairo University
Between Patient and Policy Maker - What We Can do to Build Global Capacity for Cancer Surgery
Location:Ballroom A
Ashraf Zaghloul
Zaladonis, Angela

Lankenau Medical Center
P41: A Multi-Institution Observational Analysis of the Theory of the Immunization Effect in Patients with Multiple Primary Melanomas
Location:SSO HUB: Melanoma & Sarcoma Zone
Angela Zaladonis
Zani, Sabino

Duke University Medical Center
52: Adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma confers no survival advantage.
Location:Ballroom A
Sabino Zani
P29: Hepatic resection for metastatic pancreatic ductal adenocarcinoma – a prospective single institution pilot study
Location:SSO HUB Pan-Tumor Zone: CRS, HPB, Pan-Tumor & Upper GI
Sabino Zani
P33: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer
Location:SSO HUB Pan-Tumor Zone: CRS, HPB, Pan-Tumor & Upper GI
Sabino Zani
P60: Evolution in management of upfront treatment for desmoid tumors
Location:SSO HUB: Melanoma & Sarcoma Zone
Sabino Zani
Zauderer, Maurice

Vaccinex, Inc.
38: Semaphorin 4D is Expressed by Activated Lymphocytes in Pancreatic Adenocarcinoma, and Monoclonal Blockade Sensitizes Murine Tumors to Immune Checkpoint Therapy
Location:Ballroom B
Maurice Zauderer
Zaveri, Shruti

MD Anderson Cancer Center
5: Extremely Low Incidence of Local-Regional Recurrences Observed Among T1-2 N1 (1 or 2 Positive SLNs) Breast Cancer Patients Receiving Upfront Mastectomy Without Completion Axillary Node Dissection
Location:Veterans Memorial Auditorium
Shruti Zaveri
Zebala, John

Syntrix Pharmaceuticals
P34: Determining Safety and Tolerability of SX-682 in Combination with Anti-PD1 as Maintenance Therapy for Unresectable Pancreatic Adenocarcinoma, A Phase I Study
Location:SSO HUB Pan-Tumor Zone: CRS, HPB, Pan-Tumor & Upper GI
John Zebala
Zeh, Herbert

UT Southwestern Medical Center
72: Cost Analysis and Financial Implications of Cytoreductive Surgery and HIPEC: a US Single Center Experience
Location:Ballroom B
Herbert Zeh
P18: Perioperative Outcomes of Robotic and Laparoscopic Surgery for Colorectal Cancer: A Propensity Score Matched Analysis
Location:SSO HUB Pan-Tumor Zone: CRS, HPB, Pan-Tumor & Upper GI
Herbert Zeh
Zell, Jason

University of California, Irvine
P50: Novel Vascularized Microtumor (VMT) Model of Peritoneal Carcinomatosis (PC) with Mesothelial-Lined Chambers and Submesothelial Stroma that Mimic the Peritoneal Cavity
Location:SSO HUB: Rare/Metastatic Cancers Zone
Jason Zell
Zeng, Shan

University of Pennsylvania
75: T cell Inducible Costimulator (ICOS) blockade increases the efficacy of imatinib in Gastrointestinal Stromal Tumor (GIST)
Location:Ballroom A
Shan Zeng
91: CD40 activation has direct tumor effects in gastrointestinal stromal tumor (GIST)
Location:Ballroom A
Shan Zeng
Zhang, Chi

Mayo Clinic Arizona
P31: Accuracy of DOTATATE PET/CT in the Preoperative Planning of Small Bowel Neuroendocrine Tumor Resection
Location:SSO HUB Pan-Tumor Zone: CRS, HPB, Pan-Tumor & Upper GI
Chi Zhang
Zhang, Hongji

West Virginia University
P57: Phosphorylation of IWS1 by AKT Maintains Liposarcoma Tumor Heterogeneity through Preservation of Cancer Stem Cell Phenotypes and Mesenchymal-Epithelial Plasticity
Location:SSO HUB: Melanoma & Sarcoma Zone
Hongji Zhang
Zhang, Jennifer

Hospital of the University of Pennsylvania
P67: Neighborhood Deprivation and Breast Cancer Outcomes in Philadelphia
Location:SSO HUB: Rare/Metastatic Cancers Zone
Jennifer Zhang
Zhang, Kevin

Memorial Sloan Kettering
19: Sexual Well-being in Patients with Breast Cancer Surgery: Trends, Associated Factors, and Interventions.
Location:Veterans Memorial Auditorium
Kevin Zhang
Zhang, Ping

Cooper University Hospital Department of Surgery
10: Epigenetic Drug Therapy Increases Immune Activation and Expression of Genes in the Oncotype Dx Score in Breast Cancer
Location:Veterans Memorial Auditorium
Ping Zhang
Zhang, Yaqing

University of Michigan
41: Defining the immune microenvironment surrounding pancreatic cancer using single cell RNA sequencing
Location:Ballroom B
Yaqing Zhang
Zhaoguo, Han

University of North Carolina
29: Development of a novel PET agent for parathyroid imaging targeting the Calcium-Sensing Receptor (CaSR)
Location:Ballroom A
Han Zhaoguo
Zhao, Heming

University Hospitals Cleveland Medical Center
P26: Applying 8th edition AJCC guidelines to differentiated thyroid cancer: Stage migration and impact on overall survival
Location:SSO HUB: Breast & Endocrine Zone
Heming Zhao
Zhao, Tian

OncoNano Medicine
65: Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH Sensitive Imaging Agent: Topline Results from a Phase 2 Study
Location:Veterans Memorial Auditorium
Tian Zhao
Zhao, Yujie

Merck & Co., Inc., Rahway, NJ, USA
54: Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Tumor Location in the Phase 3 KEYNOTE-716 Study
Location:Veterans Memorial Auditorium
Yujie Zhao
Zheng, Linda

American College of Surgeons
P75: “Next Gen” Operative Notes – synoptic operative reporting for cancer surgery
Location:SSO HUB: Rare/Metastatic Cancers Zone
Linda Zheng
Zhou, Helen

Carnegie Mellon University
P56: A Data Driven Approach for Individualized Risk Prediction of Serious Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Location:SSO HUB: Rare/Metastatic Cancers Zone
Helen Zhou
Zhou, Nancy

Johns Hopkins University School of Medicine
28: Tumor Deposits Are Associated with a Higher Risk of Peritoneal Disease in Non-Metastatic Colorectal Cancer Patients
Location:Ballroom C
Nancy Zhou
Zhou, Xi Kathy

New York-Presbyterian Weill Cornell Medicine
P8: Breast Cancer Among Asian Women in New York City: Disparities in Presentation and the Need for Disaggregated Data
Location:SSO HUB: Breast & Endocrine Zone
Xi Kathy Zhou
Zhou, Zhiqun

University of Miami, Miller School of Medicine, Department of Surgery
P32: p38 MAPK inhibition reprograms the inflammatory stroma to overcome the immunosuppressive tumor microenvironment in pancreatic cancer
Location:SSO HUB Pan-Tumor Zone: CRS, HPB, Pan-Tumor & Upper GI
Zhiqun Zhou
Zimmermann, Frank

University of Basel, Basel, Switzerland; Clinic of Radiation Oncology, University Hospital Basel, Basel, Switzerland
12: Impact of imaging-guided localization on performance of tailored axillary surgery in patients with clinically node-positive breast cancer: Prospective study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
Location:Veterans Memorial Auditorium
Frank Zimmermann
17: Axillary dissection to determine nodal burden to inform systemic therapy recommendations for clinically node-positive breast cancer: Pre-planned substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
Location:Veterans Memorial Auditorium
Frank Zimmermann
Zironda, Andrea

Mayo Clinic
51: Response to neoadjuvant chemotherapy in invasive intraductal papillary mucinous cystic neoplasm compared to de novo pancreatic ductal adenocarcinoma
Location:Ballroom A
Andrea Zironda
Zittel, Jazon

University of Rochester Medical Center
P34: Determining Safety and Tolerability of SX-682 in Combination with Anti-PD1 as Maintenance Therapy for Unresectable Pancreatic Adenocarcinoma, A Phase I Study
Location:SSO HUB Pan-Tumor Zone: CRS, HPB, Pan-Tumor & Upper GI
Jazon Zittel
Zuber, Samuel

North Shore University Health System
33: Validated Predictive Model for Prognosis and Treatment of Papillary Thyroid Carcinoma
Location:Ballroom A
Samuel Zuber
Zwahlen, Daniel R.

Department of Radiation Oncology, Cantonal Hospital Winterthur, Winterthur,Switzerland
12: Impact of imaging-guided localization on performance of tailored axillary surgery in patients with clinically node-positive breast cancer: Prospective study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
Location:Veterans Memorial Auditorium
Daniel R. Zwahlen
17: Axillary dissection to determine nodal burden to inform systemic therapy recommendations for clinically node-positive breast cancer: Pre-planned substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
Location:Veterans Memorial Auditorium
Daniel R. Zwahlen